Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, announced that Vikas Sharma, Ph.D., the Company’s Director, Business Development, will present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York on Wednesday, March 19, 2014. Dr. Sharma will also serve on an expert panel titled “Strategies for small molecules and biologicals drug development.” The conference will take place at New York Academy of Sciences, located at 250 Greenwich St, New York, NY. Rexahn Pharmaceuticals, Inc.(NYSEMKT:RNN) shares after opening at $1.27 on last trade day and at the end of the day closed at $1.32. Company price to cash ratio in past twelve months was calculated as 11.48. Rexahn Pharmaceuticals, Inc.(NYSEMKT:RNN) showed a positive weekly performance of 7.32%.
Palatin Technologies, Inc. (NYSE MKT:PTN) presented new analyses from its Phase 2b clinical trial of bremelanotide, which demonstrated dose-dependent improvements in sexual desire and treatment satisfaction in premenopausal women with hypoactive sexual desire disorder (HSDD) and combined HSDD/female sexual arousal disorder (FSAD), both which are forms of female sexual dysfunction (FSD).1,2,3 Palatin Technologies, Inc. (NYSEMKT:PTN) shares advanced -2.38% in last trading session and ended the day on $1.23. PTN return on equity ratio is recorded as -59.10% and its return on assets is -53.20%. Palatin Technologies, Inc. (NYSEMKT:PTN) yearly performance is 108.47%.
Aegis restated their positive rating on shares of Catalyst Pharmaceutical Partners (NASDAQ:CPRX) in a report released on Wednesday, AR Network reports. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) shares moved up 6.22% in last trading session and was closed at $2.39, while trading in range of $2.21 – $2.49. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) year to date (YTD) performance is 22.56%.
Unilife Corporation (NASDAQ:UNIS) announced that Mr. Dennis Pyers, Vice-President and Controller of Unilife since 2010, has been named Interim CFO. Mr. Pyers replaces Mr. Richard Wieland who is leaving Unilife after four years as Executive Vice President and Chief Financial Officer. Unilife Corp (NASDAQ:UNIS) weekly performance is 10.42%. On last trading day company shares ended up $5.51. Unilife Corp (NASDAQ:UNIS) distance from 50-day simple moving average (SMA50) is 22.46%. Analysts mean target price for the company is $7.70.